Nektar Therapeutics

We had a great time last weekend at #EczemaExpo2024, where Nektar proudly was a sponsor. We connected with the #eczema communities to discuss research and advancements in treatments. Learn about our promising #immunology and #inflammation pipeline of treatments that address underlying immunological dysfunctions: https://bit.ly/48e4NF2

At #EULAR2024, Nektar highlighted preclinical data from NKTR-0165, our TNFR2 agonist for the potential treatment of #autoimmune disorders. More details from the presentation here: https://bit.ly/4b9NUMa

We’re looking forward to presenting at two upcoming investor conferences in June. Join to hear about the therapies Nektar is developing across our #immunology and #inflammation pipeline and anticipated milestones ahead: https://bit.ly/4aGlRnt  

We’re excited that our Chief Research and Development Officer, Jonathan Zalevsky, will be presenting at the Annual Treg-Directed Therapies Summit this week. Learn more about his thoughts on the field of Treg therapies: https://bit.ly/3UvohPJ

Today, we announced first quarter 2024 financial results. Join us on our conference call at 5:00 p.m. ET/2:00 p.m. PT. Press release and information here: https://bit.ly/3yg5vV9

We look forward to the #Dermatology Drug Development Summit this week! Nektar’s Chief Research and Development Officer, Jonathan Zalevsky, will present on REZPEG, our lead pipeline candidate being evaluated in #inflammatory #skindiseases and will participate in a panel. For more information please visit here: https://lnkd.in/d-d2PYU

At the #WCHR2024 hosted by the American Hair Research Society, Nektar presented the trial design for the Phase 2b study of REZPEG, our lead pipeline candidate, for the treatment of #AlopeciaAreata. View our poster here: https://bit.ly/3TLPpd6   Poster Title TiP #P007: A Phase 2b Study Evaluating the Efficacy and Safety of Single Agent Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Severe to Very Severe Alopecia Areata.

We are looking forward to presenting tomorrow at the H.C. Wainwright & Co., LLC Autoimmune & Inflammatory Disease Virtual Conference. Tune in to hear about the potential of our #immunology and #inflammation pipeline to improve patient care. Webcast can be found here: https://bit.ly/3xfYumU

Today, members of our management team are presenting an overview of our #immunology pipeline and our latest company updates at the Cowen Inc. Annual Health Care Conference. Webcast Link: https://bit.ly/3wIOdPO

Today, we announced fourth quarter and year-end 2023 financial results. We will host a conference call at 5:00 p.m. ET/2:00 p.m. PT to review the results. Press release and information here: https://bit.ly/3V4mbse #immunology #inflammation